Trial intelligence / Profile preview

Efficacy and Safety of Erenumab in Episodic Migraine Prevention

NCT01952574Phase 2Completed

Sponsor
Amgen
Start
Aug 2013
Primary completion
Sep 2014
Modality
Monoclonal Antibodies
Countries
7
01

Overview

A Phase 2 trial of erenumab in migraine, sponsored by Amgen. Started Aug 2013; status: completed.

02

Drugs

erenumab
03

Conditions

migraine

Beyond the preview

Go deeper on NCT01952574.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01952574.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call